Third, NCATS runs a CTSA network of ~60 clinical and translational science institutions across country (CTSA) and runs trials such as that ACTIV1 trial of immunomodulators:
First, the release states that the vaccine worked: vaccine elicited a response and "There were no serious adverse events or safety concerns reported in the 216 trial participants"
BUT the vaccine trials will not advance to Phase 2/3, according to @CSL
WELL I'm going to have to dig into this. Reminder that vaccine development is not straightforward, despite the super-exciting day we are having watching #VRBPAC
"The UQ vaccine candidate uses a protein and adjuvant platform, containing the COVID-19 spike protein and a "molecular clamp". A small component is derived from.... HIV, that is not able to infect people or replicate."
I have a terrible feeling that ran TMPRSS2 expression on their samples, looked for a differential based on what they know about study sample donors (rather than having a hypothesis), and were like "welp, 'race' is a thing with COVID let's go with that".
I mean, there are enough studies showing this approach is not valid:
"These results suggest that .... careful consideration of self-identified race in gene expression profiling studies is needed to avoid spurious association."
OK so let's talk about camostat, because I'm starting to worry about it as a #COVID19 repurposing candidate. It emerged based on this Cell paper, but a LOT of assumptions are buried in the science. cell.com/cell/fulltext/…
That Cell paper calls camostat "calls camostat “a clinically proven inhibitor of the cellular serine protease TMPRSS2” – which is not strictly correct.
It's a serine protease inhibitor, and in Japan it's approved for treating pancreatitis. In that indiciation, doses are 600 mg are given. Data indicates it acts via anti-inflammatory action: nature.com/articles/37002…
This article on a 'miracle cure' for cancer has me so angry. How can unpublished, non-peer reviewed tripe get any attention at all? Some of the issues are in the thread below: jpost.com/HEALTH-SCIENCE…
First, the experimental theraputic modality is based on phage-display-derived peptides against various targets that are apparently coupled together with a 'peptide toxin'. Presumably the peptide toxin is Monomethyl auristatin E
Next, the article states they have "concluded its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells".